Mr Kamelhar has over 20 years of experience in the healthcare management field, with a demonstrated track record in business development, contract negotiation, financial analysis and forecasting He has proven expertise in driving efficiency, growth and productivity through evaluation of financial management systems and implementation of process improvements.

He began my career as an administrative director in managing and expanding the outpatient network development activities for Staten Island University Hospital. After obtaining his Master’s degree in Health Finance from NYU, he established the Eastchester Center for Cancer Care, a multispecialty physician group serving the greater NY area. It was here where he gained my knowledge and interest in translating promising therapeutics from late preclinical studies to early Phase I/II clinical studies. He started the center with 2 Physician and grew the practice to 11 Physicians with 70 employees with gross revenues in excess of 15 million annually.

In 2015, he founded Axella Research, a clinical research and development company to further capitalize on the infrastructure and research expertise of the network and recruit a team of experts in the research and development arena. This opened up new opportunities to collaborate with early-stage pharmaceutical companies and researchers to help develop and commercialize innovative technologies.

Positions and Honors

1998 – 2003 Administrative Director, Staten Island University Hospital, Staten Island, NY
2003 – 2017 Chief Financial Officer, Executive Director, Eastchester Center for Cancer Care, The Bronx, NY
2015 – Present Chief Executive Officer, Axella Research, Edison, NJ
2017 – 2019 Director of Business Development, NY Cancer and Blood Specialists, Jefferson Station, NY
2019 – Present Regional Director of Business Development, OneOncology, Nashville, TN

Contributions to Science

Axella Research is a small business that assists startup and early-stage biotech and pharmaceutical companies with FDA guidance and taking products from the preclinical to clinical study phases.

1. Conducted Phase IIb clinical study for novel compound to treat Nocturia
2. Conducted Phase I/II clinical study for new compound to treat Prostate Cancer
3. Conducted Investigator initiated clinical study to test the benefits of high dose vitamin C infusions in the treatment of pancreatic and ovarian cancers